Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 23, 2026CureusOpen Access

Effectiveness and Safety of Two Thrombopoietin Receptor Agonists: A Retrospective Cohort Study of Adults With Primary Immune Thrombocytopenia

View Full Paper
Ask AI
Bookmark
Share

Authors

DLDiego G LanzaLELeonardo EncisoUniversidad Nacional de ColombiaLMLuis G Moncaleano

Discussion

Loading...

Member takes

Overview

Retrospective cohort study compares effectiveness and safety of romiplostim and eltrombopag in adults with ITP, suggesting no major differences.

Key Points

  • The study aims to evaluate the effectiveness and safety of romiplostim and eltrombopag in adults with primary immune thrombocytopenia, uncovering comparative outcomes.
  • Retrospective cohort study using medical records of 58 adults with primary ITP from a university hospital in Colombia.
  • Effectiveness and safety outcomes assessed through Kaplan-Meier analysis for platelet response.
  • Median time to first platelet response was 37 days for eltrombopag and 71 days for romiplostim (p=0.50).
  • 97.3% of eltrombopag patients and 100% of romiplostim patients achieved at least one platelet response (p=1.000).
  • No significant differences in thrombotic events or treatment-related adverse events were found between groups.

Cite This Study

Lanza et al. (2026) studied this question.

synapsesocial.com/papers/6a61afe0faa9903c5116a8d8https://doi.org/10.7759/cureus.113083
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real‐world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study2024 · 23 citations
  2. 2Bridging the gaps between randomized controlled trials and real-world use of thrombopoietin receptor agonists for adult primary immune thrombocytopenia: a systematic review and meta-analysis2025 · 1 citations
  3. 3Effectiveness and Safety of Romiplostim Among Patients with Newly Diagnosed, Persistent and Chronic Immune Thrombocytopenia in European Clinical Practice2021 · 25 citations
  4. 4Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: New insights for an old treatment2021 · 36 citations
  5. 5A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia2013 · 101 citations